Uric Acid in the Comprehensive Metabolic Panel: A Case for Inclusion

Uric acid is a metabolic byproduct of purine breakdown. Purines are naturally present in the body and found in foods such as red meat, seafood, and alcohol. Under normal physiological conditions, uric acid dissolves in the bloodstream and is excreted by the kidneys through urine. When uric acid production exceeds elimination, however, it accumulates in the blood, leading to hyperuricemia, a condition associated with multiple adverse health outcomes¹.
 
Uric Acid, Gout, and Kidney Disease
 
Hyperuricemia is a well-established risk factor for gout, an inflammatory arthritis caused by the deposition of monosodium urate crystals in joints. Gout attacks are characterized by intense pain, swelling, redness, and stiffness (1). Elevated uric acid levels can also promote the formation of kidney stones, which may obstruct the urinary tract and lead to severe pain, infection, or long-term kidney damage¹.
 
Beyond Gout: Uric Acid and Metabolic Disease
 
Over the past decade, growing evidence has linked elevated uric acid levels to a broad range of metabolic disorders, including obesity, type 2 diabetes, hypertension, dyslipidemia, and cardiovascular disease²–⁵. These conditions share common pathological features such as insulin resistance, chronic low-grade inflammation, oxidative stress, and endothelial dysfunction—key drivers of heart attack, stroke, and chronic kidney disease (2-5).
 
Importantly, uric acid is no longer viewed as a passive bystander. Experimental and clinical studies suggest it may play an active role in the pathogenesis of metabolic disease.
 
Biological Mechanisms Linking Uric Acid to Metabolic Dysfunction
 
Several mechanisms have been proposed to explain how uric acid contributes to metabolic disease (2-5):
 
Inflammation activation
Uric acid can activate the NLRP3 inflammasome, a multiprotein complex that promotes the release of pro-inflammatory cytokines such as interleukin-1β and interleukin-18. These cytokines impair insulin signaling and reduce glucose uptake in muscle and liver tissue (2,3).
 
Oxidative stress and endothelial dysfunction
Elevated uric acid reduces the bioavailability of nitric oxide, a molecule essential for blood vessel dilation and vascular protection. This promotes endothelial dysfunction, raises blood pressure, and accelerates atherosclerotic plaque formation (2,4).
 
Disruption of energy metabolism
Uric acid can inhibit AMP-activated protein kinase (AMPK), a master regulator of cellular energy balance. AMPK inhibition decreases fatty acid oxidation and increases lipogenesis, contributing to hepatic fat accumulation, insulin resistance, and dyslipidemia (2,5).

Activation of the renin–angiotensin–aldosterone system (RAAS)
Uric acid may stimulate RAAS activity, increasing sodium and water reabsorption by the kidneys. This promotes hypertension and edema while simultaneously reducing uric acid excretion—creating a self-reinforcing cycle of hyperuricemia (2,4).
 
Why Isn’t Uric Acid Part of the Comprehensive Metabolic Panel?
 
Given these associations, serum uric acid is widely used as a biomarker in clinical practice—not only for gout, but also as a risk indicator for metabolic disease. Yet, uric acid is not routinely included in the Comprehensive Metabolic Panel (CMP) and is typically ordered only at the discretion of a healthcare provider (6).
 
Arguments commonly cited against its routine inclusion include:

• Cost-effectiveness: Adding uric acid to the CMP may increase testing costs, and the cost–benefit ratio of early detection remains debated.
• Risk of overdiagnosis: Detecting asymptomatic hyperuricemia could lead to unnecessary anxiety or overtreatment.
• Lack of treatment consensus: There is no universal agreement on when or how aggressively to treat elevated uric acid levels in asymptomatic individuals.

 
A Missed Opportunity for Early Prevention?
 
While further research is needed to clarify causality and define optimal uric acid ranges for disease prevention (2-5), an important question remains: How long should we wait for perfect consensus?
For asymptomatic individuals—especially younger patients or those with a family history of metabolic disease—early identification of elevated uric acid could enable low-risk interventions, such as dietary modification, weight management, and lifestyle changes. Delaying measurement until overt disease develops may represent a missed opportunity for prevention.
At present, both patients and clinicians often remain unaware of abnormal uric acid levels simply because the test is not routinely included in standard metabolic screening.
 
Time to Rethink Metabolic Panels
 
Relying solely on provider discretion may not adequately protect asymptomatic patients at risk of future metabolic disease. Government health agencies and professional medical societies should re-evaluate current guidelines and seriously consider including uric acid in metabolic panels, at least for individuals with known risk factors or a family history of metabolic disorders.
Early knowledge empowers prevention—and in the case of uric acid, the evidence increasingly suggests that earlier may be better.

References
(1) High Uric Acid Level-Causes-Mayo Clinic
(2) Controlling Uric Acid – The Key to Metabolic Health
(3) Hao-lu Sun, Yi-wan Wu, He-ge Bian, Hui Yang, Heng Wang, Xiao-ming Meng, Juan Jin (2021). Function of Uric Acid Transporters and Their Inhibitors in Hyperuricemia. Front. Pharmacol.12, Art. 667753. https://doi.org/10.3389/fphar.2021.667753
(4) Uric Acid: A Key Player in Cardio, Brain, and Metabolic Diseases
(5) Masato Furuhashi (2020). New insights into purine metabolism in metabolic diseases: role of xanthine oxidoreductase activity. Am J Physiol Endocrinol Metab 319: E827–E834. doi:10.1152/ajpendo.00378.2020
(6) Comprehensive Metabolic Panel